Please login to the form below
UCB’s Mark Bodmer elected to BIA board
Will hold the position for a three-year fixed term
UCB's Mark Bodmer has been elected to the board of UK trade body the BioIndustry Association (BIA).
Bodmer is VP, NewMedicines Therapeutics at UCB, having joined the company in 2012 as head of immunology.
As a board member of the BIA Bodmer will play a role in shaping the policy environment of the UK biotech industry. He will hold the role for three years, starting in January 2015.
Prior to joining UCB Bodmer served as senior VP of immunoinflammation, medicines discovery and development at GlaxoSmithKline.
His background also includes CEO appointments at three start-ups from 1996 to 2007: Hexagen, Lorantis and Biotica.
Featured jobs
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Science Writer – Healthcare Advertising
-
Salary TBC
- Senior Strategic Planner, Healthcare Brand Communications, Londo...
-
Competitive Salary
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Medical Writer, Healthcare Advertising
-
£35 - £45, 000 benefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Multi-Channel Account Managers - Road / Home-office based – Full...
-
Competitive salary
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Director, Training & Medical Communications, London
-
Competitive Salary
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
Subscribe to our email news alerts
- Roche starts new late-stage trials of Alzheimer’s candidate
- AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
- Moving annual total (MAT)
- Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
- Key success factor (KSF)
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- Medicen Paris Region appoints new CEO
- How can pharma build bridges with HCPs online?
- NICE set to reject Kyowa Kirin’s Crysvita for XLH
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- UK firm Nightstar bags FDA fast-track status for gene therapy
- British Business Bank sets up £2.5bn fund for ‘unicorn’ firms
PMHub
Dovetail
Transforming healthcare through effective collaboration. Making work to feel proud of.
www.dovetailstrategies.com...
Latest intelligence
- Australian Flu and the dilemma of naming diseases
- ...
- Wearables and Healthcare
- What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
- What does a future-proof rep look like?
- Businesses can no longer afford to push ahead with the traditional Key Account Management model....
Quick links
Infographics
